Dalotuzumab Biosimilar – Anti-IGF1R, CD221 mAb – Research Grade

Description of Dalotuzumab Biosimilar - Anti-IGF1R, CD221 mAb - Research Grade

Dalotuzumab Biosimilar: A Novel Anti-IGF1R Antibody for Targeted Cancer Therapy

Dalotuzumab Biosimilar, also known as Anti-IGF1R, CD221 mAb, is a monoclonal antibody that specifically targets the insulin-like growth factor 1 receptor (IGF1R). IGF1R is a cell surface receptor that plays a crucial role in cell growth and proliferation, making it an attractive therapeutic target for cancer treatment. Dalotuzumab Biosimilar is a research-grade version of the original dalotuzumab, which has shown promising results in clinical trials as a potential cancer therapy.

Structure of Dalotuzumab Biosimilar

Dalotuzumab Biosimilar is a humanized monoclonal antibody, meaning it is derived from human antibodies and has been modified to reduce its immunogenicity. It is composed of two identical heavy chains and two identical light chains, connected by disulfide bonds. The antibody has a molecular weight of approximately 150 kDa and a half-life of 12-14 days in humans.

The binding site of dalotuzumab biosimilar is located on the extracellular domain of IGF1R, specifically targeting the α-subunit of the receptor. This binding site has been designed to block the binding of IGF1 and IGF2, the natural ligands of IGF1R, thereby inhibiting the activation of downstream signaling pathways involved in cancer cell growth and survival.

Mechanism of Action

IGF1R is overexpressed in many types of cancer, including breast, lung, and colorectal cancer. This overexpression has been linked to increased cell proliferation, angiogenesis, and resistance to chemotherapy. By targeting IGF1R, dalotuzumab biosimilar aims to inhibit these processes and induce cancer cell death.

Upon binding to IGF1R, dalotuzumab biosimilar blocks the interaction between the receptor and its ligands, preventing the activation of downstream signaling pathways such as PI3K/AKT and MAPK/ERK. These pathways are important for cell survival and proliferation, and their inhibition by dalotuzumab biosimilar leads to decreased cancer cell growth and increased apoptosis.

Application of Dalotuzumab Biosimilar

Dalotuzumab biosimilar is currently being evaluated in clinical trials for the treatment of various types of cancer, including breast, lung, and colorectal cancer. In a phase II clinical trial for metastatic colorectal cancer, patients who received dalotuzumab in combination with chemotherapy showed a significant improvement in progression-free survival compared to those who received chemotherapy alone.

Furthermore, dalotuzumab biosimilar has also been studied in combination with other targeted therapies, such as cetuximab, in patients with advanced non-small cell lung cancer. The combination showed promising results, with a higher response rate and longer progression-free survival compared to cetuximab alone.

Future Directions

As dalotuzumab biosimilar continues to show promising results in clinical trials, it is expected to become an important addition to the arsenal of targeted cancer therapies. Its unique mechanism of action and potential for combination therapy make it a promising candidate for the treatment of various types of cancer.

In addition, further research is being conducted to explore the potential of dalotuzumab biosimilar in other therapeutic areas, such as diabetes and growth disorders. Its ability to specifically target IGF1R makes it a potential candidate for the treatment of these diseases.

Conclusion

Dalotuzumab biosimilar, a novel anti-IGF1R antibody, has shown promising results in clinical trials as a potential cancer therapy. Its unique mechanism of action and potential for combination therapy make it a promising candidate for the treatment of various types of cancer. As research continues, dalot